The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received ...

The FDA granted accelerated approval to telisotuzumab vedotin (Emrelis) for the treatment of adults with previously treated, ...

Diagnosed with stage 4 lung cancer in 2020, Sanjay Dutt turned to chemotherapy, exercise, and family support in his fight ...

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L ...

American depository receipts of Immutep rose after the company reported positive results from a trial of its combination treatment for non-small cell lung cancer. Immutep climbed 16% to $2.11 on ...

Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address ...

Amplia Therapeutics and Immutep have released clinical trial results that promise more effective treatments for pancreatic and lung cancers ...

Helene Duhamel was recently diagnosed with non-small cell squamous cell lung cancer. Duhamel shares her thoughts on her ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

Teos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 ...

The U.S. Food and Drug Administration (FDA) granted accelerated approval to AbbVie Inc.’s (NYSE:ABBV) Emrelis (telisotuzumab vedotin-tllv) for adult patients with locally advanced or metastatic, ...